Search This Blog

Monday, November 6, 2023

Halozyme, Acumen in License Agreement for ENHANZE® Tech in Alzheimer's

Acumen represents thirteenth license partner for ENHANZE

https://www.prnewswire.com/news-releases/halozyme-and-acumen-pharmaceuticals-enter-global-collaboration-and-non-exclusive-license-agreement-for-the-enhanze-technology-in-alzheimers-disease-301978022.html

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)